Nonagen Bioscience

Nonagen Bioscience Corporation, established in 2011, is a biotechnology company dedicated to developing advanced cancer diagnostic technologies to improve the detection of serious diseases. As a physician-led company, we focus on how science can help reduce the burden of disease, enabling patients to live better and longer lives. Currently, our work is concentrated in the field of oncology. Nonagen's primary diagnostic product, Oncuria®, is a groundbreaking multiplex immunoassay for the quantitative detection of biomarkers associated with bladder cancer in urine.